Angioplasty Balloons Market Size, Share & Trends Analysis Report By Type (Normal, DEB, Cutting, Scoring), By Application (Peripheral, Coronary), By End-use (Hospitals, ASCs, Cath Labs), By Region, And Segment Forecasts, 2023 - 2030

Angioplasty Balloons Market Size, Share & Trends Analysis Report By Type (Normal, DEB, Cutting, Scoring), By Application (Peripheral, Coronary), By End-use (Hospitals, ASCs, Cath Labs), By Region, And Segment Forecasts, 2023 - 2030

Angioplasty Balloons Market Growth & Trends

The global angioplasty balloons market size is expected to reach USD 3.24 billion by 2030, registering a CAGR of 3.9% from 2023 to 2030, according to a new report by Grand View Research, Inc. This growth is attributed to favorable government policies and increasing coronary and peripheral interventions. Angioplasty is a minimally invasive procedure, hence patients and surgeons prefer this procedure over high-cost stent placements. Furthermore, advancements in angioplasty balloons and expanding geographical reach are likely to propel the market growth in the coming years.

For instance, in December 2014, Medtronic plc received an FDA approval for their drug-coated balloon IN.PACT Admiral for the treatment of peripheral artery disease. The company also received product approval from Japanese Ministry of Health, Labor and Welfare for the treatment of peripheral artery disease in the upper leg. Approval and commercialization of cutting and scoring balloons, such as TREK and MINI TREK, AngioSculpt, and Flextome balloons along with rising adoption of new balloons are likely to drive the market further.

Angioplasty Balloons Market Report Highlights

• The normal balloons segment led the market in 2022 with a share of 54.2% due to low costs and ability of these products to treat coronary artery obstruction
• DEBs are anticipated to be the fastest-growing segment during the forecast period due to lower restenosis rate and increased R&D investments by major companies
• The coronary segment led the market with a share of 54.1% in 2022 due to the high incidence of coronary artery diseases, which are the most common type of all heart diseases
• The ASCs segment accounted for the largest share of 51.8% in 2022 and is also projected to advance at the highest CAGR of 4.1% through 2030, due to the huge demand for treatments in these settings.
• North America accounted for the maximum revenue share of 39.6% in 2022 and is expected to maintain its position during the forecast period due to the presence of major companies

Please note The report will be delivered in 2-3 business days upon order notification.